other-cancer

Improved statistical method for early cancer drug trials better identifies safe and active doses while protecting patients

Early-phase (Phase I) cancer trials are designed primarily to find the maximum tolerated dose of a new drug. But the FDA's Project Optimus initiative has pushed for reform, recognizing that the highest tolerated dose isn't always the most effective or sustainable for patients.

This paper extends an existing Bayesian trial design called BOLD with a 'backfill' component that continuously evaluates drug activity at lower doses while dose escalation proceeds. Instead of just finding the top safe dose, BF-BOLD also assesses which doses below that threshold actually show biological activity — without requiring complex statistical modeling.

Simulations show the backfill design improves both safety (fewer patients receiving overdoses) and activity assessment, leading to better-characterized recommended Phase II doses.

Key Findings

BF-BOLD extends the Bayesian Ordered Lattice Design with per-patient activity evaluation during dose escalation
Method identifies optimal biological dose (OBD) by assessing activity rates below the MTD
Simulations show improved safety and activity assessment compared to conventional designs
Backfill design reduces overdose rates in early trials
Approach is straightforward and does not require complex statistical modeling

Implications

Better Phase I trial design has downstream effects on all of drug development — getting the right dose into Phase II improves trial success rates, reduces unnecessary patient toxicity, and aligns with FDA reform goals. This has broad applicability across oncology drug development, particularly for novel targeted agents and immunotherapies where activity vs. toxicity trade-offs are complex.

Caveats

Preprint — not peer reviewed. Evidence is simulation-based, not from a real trial. Real-world implementation depends on trial sponsor and regulatory acceptance. Complexity of backfill logistics (patient enrollment, dose administration) not fully addressed.

Source: medRxiv — 2026-04-06

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.